501 related articles for article (PubMed ID: 29451706)
21. Overview of Clinical Trial Program and Applicability of Insulin Degludec/Insulin Aspart in Diabetes Management.
Bantwal G; Wangnoo SK; Shunmugavelu M; Nallaperumal S; Harsha KP; Bhattacharyya A
J Assoc Physicians India; 2015 May; 63(5 Suppl):21-8. PubMed ID: 26548031
[TBL] [Abstract][Full Text] [Related]
22. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
23. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
[TBL] [Abstract][Full Text] [Related]
24. Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
Jang HN; Yang YS; Lee SO; Oh TJ; Koo BK; Jung HS
Endocrinol Metab (Seoul); 2019 Dec; 34(4):382-389. PubMed ID: 31884738
[TBL] [Abstract][Full Text] [Related]
25. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
[TBL] [Abstract][Full Text] [Related]
26. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
[TBL] [Abstract][Full Text] [Related]
28. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST
Park SW; Bebakar WM; Hernandez PG; Macura S; Hersløv ML; de la Rosa R
Diabet Med; 2017 Feb; 34(2):174-179. PubMed ID: 26773557
[TBL] [Abstract][Full Text] [Related]
29. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
30. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
33. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
35. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
36. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
37. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
Jammah AA
Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
[TBL] [Abstract][Full Text] [Related]
38. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
[TBL] [Abstract][Full Text] [Related]
39. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
40. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
Philis-Tsimikas A; Del Prato S; Satman I; Bhargava A; Dharmalingam M; Skjøth TV; Rasmussen S; Garber AJ
Diabetes Obes Metab; 2013 Aug; 15(8):760-6. PubMed ID: 23577643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
